STOCK TITAN

Medicenna Therapeutics Corp - MDNAF STOCK NEWS

Welcome to our dedicated news page for Medicenna Therapeutics (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medicenna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medicenna Therapeutics's position in the market.

Rhea-AI Summary
Medicenna Therapeutics Corp. announces positive results from the ABILITY-1 study for MDNA11, showing a 23% response rate and promising clinical data. The company also extends its cash runway and outlines strategic plans for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.27%
Tags
earnings
-
Rhea-AI Summary
Medicenna Therapeutics Corp. announces the first patient dosed in the combination arm of the Phase 1/2 ABILITY study evaluating MDNA11 with KEYTRUDA for advanced solid tumors. MDNA11 shows promising single-agent activity and potential synergistic effects with KEYTRUDA. The company expects to report results from the study arms in H1 and H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
Rhea-AI Summary
Medicenna Therapeutics Corp. announced the appointment of MNP LLP as its new auditor, replacing PricewaterhouseCooper LLP. The Former Auditor's report for the two most recently completed financial years showed no reservations or modified opinions. The company's board of directors and audit committee approved the resignation of the Former Auditor and the appointment of MNP. Additionally, Medicenna has engaged Tandem Accounting Group Ltd. to manage its financial reporting and internal bookkeeping requirements on a contract basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Medicenna Therapeutics Corp. (MDNA) announced the initiation of enrollment in the combination arm of the Phase 1/2 ABILITY study evaluating MDNA11, a long-acting IL-2 Superkine, in combination with KEYTRUDA for the treatment of advanced solid tumors. The study aims to evaluate the potential synergistic effect of MDNA11 with KEYTRUDA in patients who do not respond or develop resistance to checkpoint therapy. MDNA11 has shown encouraging single-agent activity and is generally well tolerated. The company expects to report initial results from both the monotherapy expansion and combination escalation arms of the Phase 2 study in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
Rhea-AI Summary
Medicenna Therapeutics Corp. (MDNA) announces its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023, while continuing to trade on the Toronto Stock Exchange under its symbol MDNA. The OTCQB is the primary platform for U.S. and international companies in the entrepreneurial and development stages, providing a high-quality trading and information experience for U.S. investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
-
Rhea-AI Summary
Medicenna Therapeutics Corp. (TSX: MDNA, OTC: MDNAF) announced the Phase 2b clinical trial results of bizaxofusp, showing a 100% increase in survival benefit in unresectable recurrent glioblastoma (rGBM) patients after a single treatment. The treatment also doubled median overall survival (mOS) to 14.5 months, irrespective of IL4R expression. The data presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting highlights the promising impact of bizaxofusp in the treatment of rGBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.63%
Tags
clinical trial
Rhea-AI Summary
Medicenna Therapeutics Corp. (MDNA) extends cash runway through Q1 2025, reports positive clinical data readouts for MDNA11 and bizaxofusp. The company also announced financial results for Q2 of fiscal 2024, showing a decrease in cash and cash equivalents compared to the previous quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Medicenna Therapeutics Corp. (MDNA) to present long-term follow-up data from Phase 2b clinical trial of bizaxofusp at SNO 2023 Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.54%
Tags
conferences clinical trial
-
Rhea-AI Summary
Medicenna Therapeutics Corp. (MDNA) to present long-term follow-up data from Phase 2b clinical trial of bizaxofusp at SNO 2023 Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.58%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
conferences
Medicenna Therapeutics Corp

OTC:MDNAF

MDNAF Rankings

MDNAF Stock Data

69.64M
44.35M
23.68%
7.86%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Toronto

About MDNAF

medicenna is a clinical stage immunotherapy company developing novel highly selective versions of il-2, il-4 and il-13 superkines and first in class empowered cytokines (ecs). our mission is to become the leader in the development and commercialization of targeted ecs and superkines for the treatment of a broad range of cancers and immune-mediated diseases. we seek to achieve these successful treatments by drawing on our expertise, and that of world-class collaborators, to develop a unique set of superkines. these superkines can be developed either on their own as short or long-acting therapeutics or fused with pro-apoptotic proteins in order to precisely deliver potent cell-killing agents to the cancer cells as well as the immunosuppressive tumor micro-environment and the cancer stem cells without harming healthy cells. superkines can also be fused with other types of proteins such as antibodies to generate novel “immunocytokines” or combined with other treatment modalities such as ca